| Filed On | Filing |
|---|---|
| 28 Sep 2026 | Proxy statement: annual meeting on November 10, 2026 |
| 14 Sep 2026 | 424B5 |
| 14 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 11, 2026, BioVie Inc., a Nevada corporation (the “Company”), entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell from ti... |
| 03 Sep 2026 | SCHEDULE 13G |
| 28 Aug 2026 |
Form 4: Palumbo Joseph M, Chief Medical Officer
Bought 4,843 shares ($10.5K) |
| 28 Aug 2026 |
Form 4: Chappell Amy Suzon, Director
Bought 727 shares ($1.57K) |
| 28 Aug 2026 |
Form 4: Kim Joanne Wendy, Chief Financial Officer
Bought 2,500 shares ($5.45K) |
| 28 Aug 2026 |
Form 4: Do Cuong V, Director
Bought 15,210 shares ($31.6K) |
| 19 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | FORM S-1 AMENDMENT NO.3 |
| 13 Aug 2026 | FORM 10-K FOR PERIOD ENDED JUNE 30, 2026 |
| 07 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 07 Aug 2026 | FREE WRITING PROSPECTUS |
| 06 Aug 2026 | FREE WRITING PROSPECTUS |
| 06 Aug 2026 | FREE WRITING PROSPECTUS |
| 06 Aug 2026 | FORM S-1 AMENDMENT NO. 2 |
| 06 Aug 2026 | 8-K: Regulation FD Disclosure |
| 31 Jul 2026 | FORM S-1 AMENDMENT NO. 1 |
| 17 Jul 2026 | FORM S-1 REGISTRATION STATEMENT |
Loading...
